Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma

Proteomics - Clinical Applications

Volumn 2, Issue 7-8, 2008, Pages 1047-1057

  Weeks, Mark E ^a   Hariharan, Deepak ^a   Petronijevic, Ljiljana ^b   Radon, Tomasz R ^a   Whiteman, Hannah J ^a   Kocher, Hemant M ^a,c   Timms, John F ^d   Lemoine, Nicholas R ^a   Crnogorac Jurcevic, Tatjana ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b University Clinical Centre   (Serbia)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

2 D DIGE; Chronic pancreatitis; Pancreatic ductal adenocarcinoma; Urine

Indexed keywords

CD59 ANTIGEN; GELSOLIN; LIPOCORTIN 2; PROTEOME;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; IMMUNOBLOTTING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS;

EID: 50849103023     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780164     Document Type: Article

References (53)

1. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57, 43-66.
2. Sener, S. F., Fremgen, A., Menck, H. R., Winchester, D. P., Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 1999, 189, 1-7.
3. Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M. et al., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24, 5313-5327.
4. Egawa, S., Takeda, K., Fukuyama, S., Motoi, F. et al., Clinicopathological aspects of small pancreatic cancer. Pancreas 2004, 28, 235-240.
5. Rosty, C., Goggins, M., Early detection of pancreatic carcinoma. Hematol. Oncol. Clin. North Am. 2002, 16, 37-52.
6. Sitek, B., Luttges, J., Marcus, K., Kloppel, G. et al., Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005, 5, 2665-2679.
7. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., Li, D., Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64, 9018-9026.
8. Chen, R., Yi, E. C., Donohoe, S., Pan, S. et al., Pancreatic cancer proteome: The proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005, 129, 1187-1197.
9. Crnogorac-Jurcevic, T., Gangeswaran, R., Bhakta, V., Capurso, G. et al., Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005, 129, 1454-1463.
10. Lu, Z., Hu, L., Evers, S., Chen, J., Shen, Y., Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 2004, 4, 3975-3988.
11. Zhou, L., Lu, Z., Yang, A., Deng, R. et al., Comparative proteomic analysis of human pancreatic juice: Methodological study. Proteomics 2007, 7, 1345-1355.
12. Gronborg, M., Bunkenborg, J., Kristiansen, T. Z., Jensen, O. N. et al., Comprehensive proteomic analysis of human pancreatic juice. J. Proteome Res. 2004, 3, 1042-1055.
13. Chen, R., Pan, S., Yi, E. C., Donohoe, S. et al., Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006, 6, 3871-3879.
14. Yu, K. H., Rustgi, A. K., Blair, I. A., Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 2005, 4, 1742-1751.
15. Koomen, J. M., Shih, L. N., Coombes, K. R., Li, D. et al., Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 2005, 11, 1110-1118.
16. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J. et al., Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
17. Spahr, C. S., Davis, M. T., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary prateome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 2001, 1, 93-107.
18. Schaub, S., Wilkins, J., Weiler, T., Sangster, K. et al., Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65, 323-332.
19. Barratt, J., Topham, P., Urine proteomics: The present and future of measuring urinary protein components in disease. CMAJ 2007, 177, 361-368.
20. Thongboonkerd, V., Genomics, proteomics and integrative "omics" in hypertension research. Curr. Opin. Nephrol. Hypertens 2005, 14, 133-139.
21. Comte, B., Franceschi, C., Sadoulet, M. O., Silvy, F. et al., Detection of bile salt-dependent lipase, a 110 kDa pancreatic protein, in urines of healthy subjects. Kidney Int. 2006, 69, 1048-1055.
22. Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V., Mann, M., The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006, 7, R80.
23. Theodorescu, D., Wittke, S., Ross, M. M., Walden, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol. 2006, 7, 230-240.
24. Tantipaiboonwong, P., Sinchaikul, S., Sriyam, S., Phutrakul, S., Chen, S. T., Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 2005, 5, 1140-1149.
25. Ye, B., Skates, S., Mok, S. C., Horick, N. K. et al., Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12, 432-441.
26. Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E., Moses, M. A., ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J. Biol. Chem. 2004, 279, 51323-51330.
27. Chan, H. L., Gharbi, S., Gaffney, P. R., Cramer, R. et al., Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5, 2908-2926.
28. Weeks, M. E., Sinclair, J., Butt, A., Chung, Y. L. et al., A parallel proteomic and metabolomic analysis of the hydrogen peroxide- and Sty1p-dependent stress response in Schizosaccharomyces pombe. Proteomics 2006, 6, 2772-2796.
29. Schmidt, F., Schmid, M., Jungblut, P. R., Mattow, J. et al., Iterative data analysis is the key for exhaustive analysis of peptide mass fingerprints from proteins separated by two-dimensional electrophoresis. J. Am. Soc. Mass Spectrom. 2003, 14, 943-956.
30. Smith, G., Barratt, D., Rowlinson, R., Nickson, J., Tonge, R., Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis. Proteomics 2005, 5, 2315-2318.
31. Chelala, C., Hahn, S. A., Whiteman, H. J., Barry, S. et al., Pancreatic Expression database: A generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics 2007, 8, 439.
32. Kersey, P. J., Duarte, J., Williams, A., Karavidopoulou, Y. et al., The International Protein Index: An integrated database for proteomics experiments. Proteomics 2004, 4, 1985-1988.
33. Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K. F. et al., From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res. 2006, 34, D354-D357.
34. Sun, W., Li, F., Wu, S., Wang, X. et al., Human urine proteome analysis by three separation approaches. Proteomics 2005, 5, 4994-5001.
35. Bottini, P. V., Ribeiro Alves, M. A., Garlipp, C. R., Electrophoretic pattern of concentrated urine: Comparison between 24-hour collection and random samples. Am. J. Kidney Dis. 2002, 39, E2.
36. Watson, N. F., Durrant, L. G., Madjd, Z., Ellis, I. O. et al., Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 2006, 55, 973-980.
37. Madjd, Z., Pinder, S. E., Paish, C., Ellis, I. O. et al., Loss of CD59 expression in breast tumours correlates with poor survival. J. Pathol. 2003, 200, 633-639.
38. Crnogorac-Jurcevic, T., Efthimiou, E., Nielsen, T., Loader, J. et al., Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002, 21, 4587-4594.
39. Rother, R. P., Zhao, J., Zhou, Q., Sims, P. J., Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59. J. Biol. Chem. 1996, 271, 23842-23845.
40. Waisman, D. M., Annexin II tetramer: Structure and function. Mol. Cell. Biochem. 1995, 149-150, 301-322.
41. Esposito, I., Penzel, R., Chaib-Harrireche, M., Barcena, U. et al., Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J. Pathol. 2006, 208, 673-685.
42. Chen, R., Brentnall, T. A., Pan, S., Cooke, K. et al., Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell. Proteomics 2007, 6, 1331-1342.
43. Ulvestad, E., Kristoffersen, E. K., Jensen, T. S., Matre, R., Identification of a soluble Fc gamma-binding molecule (annexin II) in human serum using a competitive ELISA. APMIS 1994, 102, 667-673.
44. Silacci, P., Mazzolai, L., Gauci, C., Stergiopulos, N. et al., Gelsolin superfamily proteins: Key regulators of cellular functions. Cell Mol. Life Sci. 2004, 61, 2614-2623.
45. Thompson, C. C., Ashcroft, F. J., Patel, S., Saraga, G. et al., Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut. 2007, 56, 95-106.
46. Gebhardt, C., Nemeth, J., Angel, P., Hess, J., S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006, 72, 1622-1631.
47. Sheikh, A. A., Vimalachandran, D., Thompson, C. C., Jenkins, R. E. et al., The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 2007, 7, 1929-1940.
48. Evans, P. C., Taylor, E. R., Coadwell, J., Heyninck, K. et al., Isolation and characterization of two novel A20-like proteins. Biochem. J. 2001, 357, 617-623.
49. Evans, P. C., Ovaa, H., Hamon, M., Kilshaw, P. J. et al., Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 2004, 378, 727-734.
50. Ohuchida, K., Mizumoto, K., Ishikawa, N., Fujii, K. et al., The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin. Cancer Res. 2005, 11, 7785-7793.
51. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
52. Anderson, N. G., Anderson, N. L., Tollaksen, S. L., Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis. Clin. Chem. 1979, 25, 1199-1210.
53. Morkbak, A. L., Pedersen, J. F., Nexo, E., Glycosylation independent measurement of the cobalamin binding protein haptocorrin. Clin. Chim. Acta 2005, 356, 184-190.